Blue Barn Wealth LLC Lowers Position in Johnson & Johnson (NYSE:JNJ)

Blue Barn Wealth LLC decreased its position in Johnson & Johnson (NYSE:JNJ) by 7.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,062 shares of the company’s stock after selling 166 shares during the period. Blue Barn Wealth LLC’s holdings in Johnson & Johnson were worth $320,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Sierra Capital LLC raised its position in shares of Johnson & Johnson by 0.6% during the fourth quarter. Sierra Capital LLC now owns 10,036 shares of the company’s stock worth $1,773,000 after purchasing an additional 61 shares during the period. MTM Investment Management LLC raised its position in shares of Johnson & Johnson by 0.5% during the first quarter. MTM Investment Management LLC now owns 11,283 shares of the company’s stock worth $1,749,000 after purchasing an additional 61 shares during the period. Lockerman Financial Group Inc. raised its position in shares of Johnson & Johnson by 2.4% during the fourth quarter. Lockerman Financial Group Inc. now owns 2,684 shares of the company’s stock worth $474,000 after purchasing an additional 62 shares during the period. OneAscent Financial Services LLC raised its position in shares of Johnson & Johnson by 3.3% during the first quarter. OneAscent Financial Services LLC now owns 1,986 shares of the company’s stock worth $308,000 after purchasing an additional 63 shares during the period. Finally, Addison Advisors LLC raised its position in shares of Johnson & Johnson by 0.8% during the fourth quarter. Addison Advisors LLC now owns 7,862 shares of the company’s stock worth $1,389,000 after purchasing an additional 64 shares during the period. Hedge funds and other institutional investors own 68.40% of the company’s stock.

Insider Activity

In related news, EVP Kathryn E. Wengel sold 12,465 shares of the stock in a transaction dated Monday, June 12th. The stock was sold at an average price of $160.00, for a total transaction of $1,994,400.00. Following the sale, the executive vice president now owns 65,934 shares of the company’s stock, valued at approximately $10,549,440. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider William Hait sold 14,698 shares of the stock in a transaction dated Wednesday, July 26th. The stock was sold at an average price of $172.00, for a total transaction of $2,528,056.00. Following the sale, the insider now owns 87,747 shares of the company’s stock, valued at approximately $15,092,484. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Kathryn E. Wengel sold 12,465 shares of the firm’s stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $160.00, for a total value of $1,994,400.00. Following the completion of the sale, the executive vice president now directly owns 65,934 shares in the company, valued at approximately $10,549,440. The disclosure for this sale can be found here. Insiders have sold 47,163 shares of company stock valued at $7,928,856 in the last 90 days. Insiders own 0.20% of the company’s stock.

Analysts Set New Price Targets

JNJ has been the topic of a number of research reports. Stifel Nicolaus upped their target price on Johnson & Johnson from $165.00 to $175.00 in a research report on Friday, July 21st. Morgan Stanley reiterated an “equal weight” rating and set a $187.00 price target on shares of Johnson & Johnson in a report on Friday, July 21st. Citigroup started coverage on Johnson & Johnson in a report on Tuesday, May 30th. They set a “buy” rating and a $185.00 price target for the company. Atlantic Securities upped their price target on Johnson & Johnson from $167.00 to $170.00 and gave the stock a “neutral” rating in a report on Friday, August 4th. Finally, Credit Suisse Group upped their price target on Johnson & Johnson from $170.00 to $175.00 and gave the stock a “neutral” rating in a report on Friday, July 21st. Eight research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $171.80.

Johnson & Johnson Stock Up 0.0 %

Shares of NYSE:JNJ opened at $164.31 on Wednesday. The company has a market capitalization of $427.04 billion, a PE ratio of 33.26, a price-to-earnings-growth ratio of 2.76 and a beta of 0.54. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.12 and a quick ratio of 0.88. The business has a fifty day moving average price of $166.68 and a two-hundred day moving average price of $161.50. Johnson & Johnson has a 1 year low of $150.11 and a 1 year high of $181.04.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Thursday, July 20th. The company reported $2.80 EPS for the quarter, beating analysts’ consensus estimates of $2.62 by $0.18. Johnson & Johnson had a return on equity of 36.72% and a net margin of 13.35%. The firm had revenue of $25.53 billion for the quarter, compared to analysts’ expectations of $24.63 billion. During the same quarter in the prior year, the firm earned $2.59 EPS. The business’s revenue for the quarter was up 6.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.75 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, September 7th. Stockholders of record on Monday, August 28th will be given a dividend of $1.19 per share. The ex-dividend date is Friday, August 25th. This represents a $4.76 dividend on an annualized basis and a dividend yield of 2.90%. Johnson & Johnson’s dividend payout ratio is presently 96.36%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.